Axonics Modulation Technologies ( (AXNX) ) has released its Q3 earnings. Here is a breakdown of the information Axonics Modulation Technologies ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Shares of Axonics, Inc. (NASDAQ:AXNX – Get Free Report) have been given an average recommendation of “Hold” by the nine ...

Axonics (NASDAQ:AXNX) quickly rose 1% after Boston Scientific (BSX) said it will no longer offer Coaptite as of Nov. 1. Investors believe the announcement may mean that Boston Scientific (BSX ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Axonics Modulation Technologies Inc. (AXNX) on Thursday reported a third-quarter loss of $21,000, after reporting a profit in the same period a year earlier ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ...

Axonics founder and CEO Raymond Cohen accepts a Business Journal Innovator of the Year award during a Sept. 12 ceremony. Axonics Inc. (Nasdaq: AXNX), a maker of medical devices to treat incontinence, ...

In this article, we are going to take a look at where Axonics, Inc. (NASDAQ:AXNX) stands in the list of George Soros Net Worth and Top 10 Holdings in 2024. George Soros is one of the biggest ...

Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The company had revenue of $114.57 million for the quarter, compared to analyst estimates of $112.83 million.

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel ...

Axonics Shares Fall Despite Australia's Approval for R20 SNM Device Axonics, Inc. (NASDAQ: AXNX) has received regulatory approval from the Therapeutic Goods Administration to market its R20 ...